Galcanezumab (Emgality®). HTA ID 20052
Galcanezumab is indicated for the prophylaxis of migraine in adults who have at least four migraine days per month.
| NCPE Assessment Process | Complete |
| Rapid review commissioned | 02/12/2020 |
| Rapid review completed | 13/01/2021 |
| Rapid Review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of galcanezumab (Emgality®) on the basis of the proposed price relative to currently available therapies. |